Entecavir Monohydrate
产品说明书
 |
同义名 : | 恩替卡韦一水合物 ;BMS200475 monohydrate; SQ34676 monohydrate; SQ 34,676; BMS 200475; Entecavir(hydrate); Entecavir Hydrate; Entecavir(monohydrate) |
| CAS号 : | 209216-23-9 | |
| 货号 : | A148639 | |
| 分子式 : | C12H17N5O4 | |
| 纯度 : | 98% | |
| 分子量 : | 295.29 | |
| MDL号 : | MFCD09754448 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(169.32 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 2.5 mg/mL(8.47 mM) |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Entecavir (ETV) Monohydrate is a first-line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance[3]. Entecavir, a new deoxyguanosine analog, represents a third agent within the nucleoside/nucleotide HBV polymerase inhibitor class with distinct advantages over lamivudine and adefovir dipivoxil: it has a three-step mechanism of action, is the most potent inhibitor of HBV DNA polymerase, is not associated with any major adverse effects, and has a limited potential for resistance. In phase II and III clinical trials, entecavir was found to be superior to lamivudine for all primary endpoints evaluated in both nucleoside-naïve and lamivudine-resistant patients. Entecavir was effective in both HBeAg-positive and HBeAg-negative nucleoside-naïve patients[4]. In chronic hepatitis B patients experiencing clevudine-induced myopathy, switching to entecavir 0.5 mg per day showed a resolution of myopathy and adequate viral suppression[5]. Entecavir (ETV) resistance of hepatitis B virus (HBV) conventionally requires rt184, 202, or 250 mutations plus lamivudine-resistance mutation (rtM204V/I ± L180M)[6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.39mL 0.68mL 0.34mL |
16.93mL 3.39mL 1.69mL |
33.87mL 6.77mL 3.39mL |
| 参考文献 |
|---|